Craig L Slingluff, Jr [clinicaltrials_resource:8e0e60bb9ce68a4f2bebd75bf753b2a7]
Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma [clinicaltrials:NCT00089193]Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma [clinicaltrials:NCT00118313]clinicaltrials:NCT00373217Vaccine Therapy in Treating Patients With Advanced Melanoma [clinicaltrials:NCT00705640]Study to Assess the Safety and Immunological Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI [clinicaltrials:NCT01425749]clinicaltrials:NCT01585350clinicaltrials:NCT02126579clinicaltrials:NCT02425306
collaborator [clinicaltrials_vocabulary:collaborator]
Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma [clinicaltrials:NCT00089193]Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma [clinicaltrials:NCT00118313]clinicaltrials:NCT00373217Vaccine Therapy in Treating Patients With Advanced Melanoma [clinicaltrials:NCT00705640]Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma [clinicaltrials:NCT00938223]Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma [clinicaltrials:NCT00977145]Study to Assess the Safety and Immunological Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI [clinicaltrials:NCT01425749]clinicaltrials:NCT01532960clinicaltrials:NCT01585350Evaluation of a Multi-phosphopeptide Vaccine Plus PolyICLC in Participants With High Risk and Advanced Malignancies [clinicaltrials:NCT01846143]clinicaltrials:NCT02126579A Clinical Trial to Evaluate a Helper Peptide Vaccine Plus Vemurafenib in Melanoma [clinicaltrials:NCT02382549]A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma [clinicaltrials:NCT02385669]clinicaltrials:NCT02425306Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab [clinicaltrials:NCT02515227]
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
Craig L Slingluff, Jr [clinicaltrials_resource:8e0e60bb9ce68a4f2bebd75bf753b2a7]
Bio2RDF identifier
8e0e60bb9ce68a4f2bebd75bf753b2a7
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:8e0e60bb9ce68a4f2bebd75bf753b2a7
organization [clinicaltrials_vocabulary:organization]
identifier
clinicaltrials_resource:8e0e60bb9ce68a4f2bebd75bf753b2a7
title
Craig L Slingluff, Jr
@en
type
label
Craig L Slingluff, Jr [clinicaltrials_resource:8e0e60bb9ce68a4f2bebd75bf753b2a7]
@en